These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28833362)

  • 41. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
    Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerclage, progesterone and α-hydroxyprogeterone caproate treatment in women at risk for preterm delivery.
    Haram K; Mortensen JH; Morrison JC
    J Matern Fetal Neonatal Med; 2014 Nov; 27(16):1710-5. PubMed ID: 24678618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
    Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
    Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
    Heyborne KD; Allshouse AA; Carey JC
    Am J Obstet Gynecol; 2015 Dec; 213(6):844.e1-6. PubMed ID: 26275354
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 17-hydroxyprogesterone caproate, progesterone, preterm birth prevention, and safety: who decides? Someone should.
    O'Brien JM
    Am J Obstet Gynecol; 2011 May; 204(5):e16-7; author reply e17. PubMed ID: 21276949
    [No Abstract]   [Full Text] [Related]  

  • 46. Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention: does timing of initiation and compliance matter?
    Carter EB; Cahill AG; Olsen MA; Macones GA; Tuuli MG; Stout MJ
    J Perinatol; 2019 Sep; 39(9):1182-1189. PubMed ID: 31217529
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM; Istwan NB; Palmer B; Stanziano GJ
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inequality and Innovation: Barriers and Facilitators to 17P Administration to Prevent Preterm Birth among Medicaid Participants.
    Cross-Barnet C; Benatar S; Courtot B; Hill I; Johnston E; Cheeks M
    Matern Child Health J; 2018 Nov; 22(11):1607-1616. PubMed ID: 29956128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment options and recommendations to reduce preterm births in women with short cervix.
    Slager J; Lynne S
    J Midwifery Womens Health; 2012 Jul; 57 Suppl 1():S12-8. PubMed ID: 22776244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
    Spong CY; Meis PJ; Thom EA; Sibai B; Dombrowski MP; Moawad AH; Hauth JC; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of Preterm Labor with 17α-Hydroxyprogesterone (17OHP) Caproate: A Comparison of Adverse Drug Reaction Rates between Compounded and Commercial Formulations.
    Stone RH; Bobowski C; Milikhiker N; Anguiano RH; Mastrogiannis D
    Am J Perinatol; 2017 Dec; 34(14):1436-1441. PubMed ID: 28704849
    [No Abstract]   [Full Text] [Related]  

  • 52. Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention.
    Zhang S; Rascati KL
    Curr Med Res Opin; 2021 Sep; 37(9):1667-1675. PubMed ID: 34030550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The rebirth of progesterone in the prevention of preterm labor.
    Schmouder VM; Prescott GM; Franco A; Fan-Havard P
    Ann Pharmacother; 2013 Apr; 47(4):527-36. PubMed ID: 23535817
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined treatment with cervical pessary and vaginal progesterone for the prevention of preterm birth: A randomized clinical trial.
    Karbasian N; Sheikh M; Pirjani R; Hazrati S; Tara F; Hantoushzadeh S
    J Obstet Gynaecol Res; 2016 Dec; 42(12):1673-1679. PubMed ID: 27718280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progesterone for Prevention of Preterm Birth: Shortcomings and Unintended Consequences of the Orphan Drug Act.
    Gee RE; Kuy S; Karas LO
    Obstet Gynecol; 2017 Dec; 130(6):1202-1206. PubMed ID: 29112651
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
    Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
    Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
    Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
    Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice.
    Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella
    Am J Obstet Gynecol; 2012 May; 206(5):376-86. PubMed ID: 22542113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth.
    Heyborne KD; Allshouse AA
    Am J Perinatol; 2016 Oct; 33(12):1191-7. PubMed ID: 27464018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
    Timofeev J; Feghali M; Boyle A; Istwan N; Rhea D; Driggers RW
    J Matern Fetal Neonatal Med; 2013 Jun; 26(9):881-4. PubMed ID: 23311766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.